B. Riley Estimates OptimizeRx’s Q1 Earnings (NASDAQ:OPRX)

OptimizeRx Co. (NASDAQ:OPRX) – Investment analysts at B. Riley issued their Q1 2025 earnings estimates for shares of OptimizeRx in a note issued to investors on Wednesday, March 12th. B. Riley analyst A. Schock forecasts that the company will earn ($0.34) per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for OptimizeRx’s current full-year earnings is ($0.33) per share. B. Riley also issued estimates for OptimizeRx’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($0.27) EPS.

OPRX has been the subject of several other research reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 price objective on shares of OptimizeRx in a report on Tuesday, December 24th. Stephens assumed coverage on shares of OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price for the company. Finally, JMP Securities restated a “market outperform” rating and set a $8.00 price target on shares of OptimizeRx in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Stock Performance

Shares of OPRX opened at $8.27 on Monday. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $14.13. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a 50 day moving average price of $5.58 and a two-hundred day moving average price of $5.90. The firm has a market capitalization of $152.34 million, a P/E ratio of -6.22 and a beta of 1.31.

Institutional Trading of OptimizeRx

A number of large investors have recently added to or reduced their stakes in OPRX. SBI Securities Co. Ltd. bought a new position in shares of OptimizeRx during the 4th quarter valued at approximately $25,000. BNP Paribas Financial Markets lifted its stake in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares during the last quarter. SG Americas Securities LLC purchased a new position in OptimizeRx in the fourth quarter valued at approximately $51,000. Wells Fargo & Company MN grew its holdings in OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock valued at $54,000 after purchasing an additional 2,797 shares during the period. Finally, Quest Partners LLC increased its position in OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.